Kristen E Jones

US Patent:

20100093811, Apr 15, 2010

Filed:

Sep 22, 2008

Appl. No.:

12/523200

Inventors:

Craig A. Coburn - Royersford PA, US
Joseph P. Vacca - Telford PA, US
Hemaka A. Rajapakse - Wyncote PA, US
Kristen L.G. Jones - Jeffersonville PA, US
Philippe Nantermet - Lansdale PA, US
James C. Barrow - Harleysville PA, US
Keith P. Moore - Harleysville PA, US
Steven S. Sharik - Ambler PA, US
Cory Theberge - Elkins Park PA, US
Abbas M. Walji - Lansdale PA, US

International Classification:

A61K 31/44
C07C 311/15
A61K 31/18
C07C 271/06
A61K 31/27
C07D 277/62
A61K 31/426
C07D 213/55
A61P 31/18

US Classification:

514357, 564 86, 514603, 560115, 514487, 548178, 514367, 546335

Abstract:

Compounds of Formula I are disclosed: (I), wherein X, k, R, R, R, R, R, R, R, R, Rand Rare defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

US Patent:

20220289710, Sep 15, 2022

Filed:

May 24, 2022

Appl. No.:

17/752419

Inventors:

- Rahway NJ, US
Ian M. Bell - Harleysville PA, US
Michael J. Breslin - Drexel Hill PA, US
Christopher James Bungard - Lansdale PA, US
Christopher S. Burgey - Ambler PA, US
Harry R. Chobanian - Westfield NJ, US
Jason M. Cox - Rancho Santa Fe CA, US
Anthony T. Ginnetti - Perkasie PA, US
Deodial Guy Guiadeen - Chesterfield NJ, US
Kristen L.G. Jones - Oreland PA, US
Mark E. Layton - Harleysville PA, US
Hong Liu - Hillsborough NJ, US
Jian Liu - Norristown PA, US
James J. Perkins - Churchville PA, US
Shawn J. Stachel - Perkasie PA, US
Zhe Wu - Blue Bell PA, US

Assignee:

Merck Sharp & Dohme LLC - Rahway NJ

International Classification:

C07D 401/12
C07D 401/14
C07D 409/14
C07D 413/14
C07D 417/14
C07D 471/04
C07D 491/04
C07D 471/08
C07D 487/04
C07D 491/048
C07D 495/04

Abstract:

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

US Patent:

20190185462, Jun 20, 2019

Filed:

Jun 19, 2017

Appl. No.:

16/309390

Inventors:

- Rahway NJ, US
Richard Berger - Harleysville PA, US
Craig A. Stump - Pottstown PA, US
Kelly Ann S. Schlegel - Fleetwood PA, US
James J. Mulhearn - Elkins, PA
Thomas J. Greshock - Collegeville PA, US
Deping Wang - Furlong PA, US
Mark E. Fraley - North Wales PA, US
Kristen G. Jones - Oreland PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 413/10
C07D 413/14
C07D 413/04
C07D 413/12
C07D 417/12
C07D 417/14
C07D 471/04
C07D 487/04
C07D 491/048
C07D 491/052
C07D 498/04
C07D 513/04
C07D 271/06
C07D 471/14
A61P 25/28
A61P 25/18
A61P 29/00
A61P 11/06
A61P 3/10
A61P 35/00
A61P 37/02

Abstract:

The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.